Top Pharmaceutical Companies in Seattle, WA (17)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability & Growth Strengths
Product Line Growth: Growth across non‑COVID medicines such as Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec/Vydura and oncology biosimilars has been robust. Launched and acquired products are showing sustained double‑digit operational gains, adding meaningful momentum.
Resilient & Sustainable Growth: Excluding COVID products, the underlying portfolio delivered mid‑single‑digit operational growth in 2025 and continued at a similar pace in early 2026, more than offsetting part of the COVID‑related decline. Reported revenue also returned to modest year‑over‑year growth in the first half of 2026, indicating stabilization.
Future-Ready Strategy: Management raised the midpoint of 2026 revenue guidance and continues to invest heavily in a broad late‑stage pipeline. This posture signals confidence that newer launches and acquired assets can drive the next leg of growth.
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
The District Council of Madison Inc., Society of St. Vincent de Paul is a Catholic nonprofit organization based in Madison, Wisconsin. It serves neighbors in need by providing essential resources, including food distribution, charitable pharmacy services, housing support, and financial assistance. These programs are funded by a network of thrift stores, focusing on empowering individuals and families facing hardship to...
Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade. The company is based on technology and compounds exclusively licensed from the University of Washington. The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late...
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. We are powered...
Novo Nordisk's Top Stability & Growth Strengths
Strong Market Position & Advantage: Novo Nordisk is characterized as a global leader in GLP‑1–based diabetes and obesity care, anchored by clinically differentiated products like Wegovy and a broad GLP‑1 portfolio. While shares fluctuate by geography, disclosures and independent analyses continue to frame the company as a category leader.
Innovation-Driven Growth: Cardiovascular outcomes data supporting Wegovy’s label expansion and the first approved oral GLP‑1 for chronic weight management, together with late‑stage assets (e.g., amycretin/zenagamtide, CagriSema), strengthen adoption arguments and extend the franchise.
Market Expansion: U.S. launch momentum for the Wegovy pill, EU approval, and planned international rollouts in 2026 are broadening access and the addressable market. Significant capacity additions, including acquired fill‑finish sites and new investments, are intended to support higher volumes across regions.
Navigating Cancer is the leading digital health solution for oncology. We focus on improving the patient experience, delivering more effective care management, and enabling oncology care innovation.
Aurion Biotech, Inc. is a clinical-stage biotechnology company focused on restoring vision through regenerative cell therapies. Founded in 2021 with offices in Seattle, Boston and Tokyo, Aurion develops AURN001, a cultured corneal endothelial cell therapy to treat corneal edema from endothelial dysfunction. The company has advanced clinical programs, regulatory designations, and commercial activity in Japan, aiming to scale donor-cell culture...
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with...
By unlocking skin biology and applying advanced engineering and software, via its patented microarray patch (MAP), Panther is delivering a comprehensive pipeline of shelf-stable treatments directly to consumers globally. Panther is reshaping healthcare with its compelling end-to-end user experience, and is making its platform available to skincare, pharma, biotech and other partners.
LeonaBio is dedicated to the development of novel therapeutics for diseases with high unmet needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patient’s lives.
Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune...
Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies
We’re designing a better way to deliver and pay for health while engaging and guiding a community of members to live their best health. As a national, team-based medical group with a focus on wellbeing and prevention that extends beyond traditional sick care, we deliver Primary Health. An entirely new model of health, Primary Health is driven by an interdisciplinary...
CarepathRx is transforming pharmacy care delivery for health systems and hospitals, delivering improved patient outcomes that drive clinical, quality and financial results. CarepathRx provides the industry’s most comprehensive hospital pharmacy care delivery model, providing support across the patient’s complete healthcare journey—across multiple care settings, from hospital to home, no matter the patient acuity level. We take an enterprise approach to pharmacy...
Omeros is a Seattle-based commercial-stage biopharmaceutical company that discovers, develops, and commercializes first-in-class small-molecule and protein therapeutics for large-market and orphan indications. Its programs focus on complement-mediated diseases, inflammation, cancers, and addictive or compulsive disorders. The company’s pipeline includes FDA-approved YARTEMLEA, the investigational MASP-2 inhibitor OMS1029, OMS527 in clinical development, and a growing portfolio of molecular and cellular oncology programs.
